Non Invasive Ultrasound Neuromodulation Systems Market

According to Stratistics MRC, the Global Non-Invasive Ultrasound Neuromodulation Systems Market is accounted for $0.8 billion in 2026 and is expected to reach $3.6 billion by 2034, growing at a CAGR of 20.7% during the forecast period. Non-Invasive Ultrasound Neuromodulation Systems utilize focused ultrasound energy to influence neural activity without surgical implantation or direct electrical stimulation. Increasing prevalence of neurological and psychiatric disorders, growing demand for non-invasive treatment alternatives, and expanding neuroscience research are driving market development. Technological advancements in low-intensity focused ultrasound, transcranial pulse stimulation, and image-guided targeting are improving neuromodulation precision. Growing investment in personalized brain stimulation, neurorehabilitation, and adaptive neuromodulation technologies is creating opportunities across hospitals, specialty clinics, and research institutions.

Market Dynamics:

Driver:

Increasing demand for non-invasive neurological treatment and targeted brain stimulation

Increasing demand for non-invasive neurological treatment and targeted brain stimulation is driving development of ultrasound neuromodulation systems. Researchers and healthcare providers are investigating focused ultrasound technologies for modulating neural circuits associated with neurological and psychiatric conditions. These systems offer potential advantages through targeted stimulation without implanted electrodes. Growing neurological disease prevalence, expanding brain stimulation research, and interest in alternative treatment approaches encourage development. Advances in ultrasound transducers, neuronavigation, and stimulation protocols further strengthen market prospects.

Restraint:

Limited clinical validation and high costs of specialized neuromodulation systems

Limited clinical validation and high costs of specialized neuromodulation systems restrain market adoption. Focused ultrasound neuromodulation requires precise targeting, carefully controlled acoustic parameters, and specialized equipment to ensure consistent stimulation. Differences in skull characteristics, neural anatomy, and treatment protocols complicate standardization. Limited regulatory approvals and reimbursement pathways restrict routine clinical implementation. Healthcare organizations may hesitate to invest in advanced systems without stronger evidence demonstrating long-term safety, therapeutic effectiveness, and cost-effectiveness.

Opportunity:

Expansion of personalized ultrasound stimulation and adaptive neuromodulation platforms

Expansion of personalized ultrasound stimulation and adaptive neuromodulation platforms presents significant growth opportunities. Advanced systems integrate neuroimaging, neuronavigation, and computational modeling to improve targeting of specific brain regions. Closed-loop technologies could incorporate physiological feedback to adjust stimulation parameters according to individual responses. Growing research into depression, cognitive disorders, chronic pain, and neurological rehabilitation encourages innovation. Increasing investment in portable ultrasound devices, artificial intelligence, and individualized treatment planning supports technological development.

Threat:

Competition from established neuromodulation therapies and neurological safety concerns

Competition from established neuromodulation therapies and neurological safety concerns pose significant challenges to ultrasound neuromodulation systems. Transcranial magnetic stimulation, transcranial electrical stimulation, and implanted neurostimulation devices have established clinical applications and treatment pathways. Potential risks associated with inappropriate ultrasound exposure, inconsistent targeting, and uncertain long-term neurological effects require careful investigation. Increasing regulatory scrutiny, complex clinical trial requirements, and limited reimbursement opportunities create commercialization barriers. Developers must demonstrate reliable safety and clinical effectiveness to achieve broader adoption.

Covid-19 Impact:

The COVID-19 pandemic disrupted neurological research programs, clinical trials, and medical equipment installations, affecting development of ultrasound neuromodulation systems. Restrictions on hospital access and laboratory activities delayed experimental studies and patient recruitment. However, increasing attention to neurological complications, mental health conditions, and non-invasive therapeutic approaches encouraged continued research interest. Subsequent recovery in neuroscience funding, renewed clinical investigation, and expanding investment in advanced brain stimulation technologies continue to support market development.

The integrated ultrasound neuromodulation systems segment is expected to be the largest during the forecast period

The integrated ultrasound neuromodulation systems segment is expected to account for the largest market share during the forecast period due to demand for comprehensive platforms combining ultrasound generation, targeting, monitoring, and stimulation control. These systems support specialized neurological research and emerging clinical investigations requiring precise acoustic delivery. Increasing investment in hospital-based neuromodulation infrastructure, neuroscience laboratories, and advanced therapeutic development encourages adoption. Integration with neuroimaging, neuronavigation, and computational planning technologies strengthens system capabilities and supports segment growth.

The portable & wearable neuromodulation systems segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the portable & wearable neuromodulation systems segment is predicted to witness the highest growth rate due to increasing interest in accessible and flexible brain stimulation technologies. Compact ultrasound devices could support simplified treatment workflows and research applications beyond specialized laboratory environments. Advances in transducer miniaturization, power management, and automated stimulation control improve development prospects. Growing investment in personalized neuromodulation, decentralized neurological care, and portable therapeutic platforms is expected to accelerate innovation and potential adoption.

Region with largest share:

During the forecast period, North America is expected to hold the largest share due to advanced neuroscience research infrastructure, substantial medical technology investment, and extensive neuromodulation development activities. The United States leads regional innovation through research universities, medical device companies, and neurological treatment centers investigating focused ultrasound technologies. Increasing investment in brain stimulation research, precision neurotherapeutics, and clinical trials encourages development. Partnerships between technology manufacturers, academic institutions, and healthcare providers strengthen regional commercialization prospects.

Region with highest CAGR:

Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding neuroscience research infrastructure, increasing healthcare investment, and growing interest in non-invasive neurological therapies. China, Japan, India, South Korea, and Australia are advancing focused ultrasound research and brain stimulation technologies. Improving access to advanced medical equipment, expanding neurological research programs, and increasing investment in neurotechnology encourage development. Government research initiatives and collaborations between medical device manufacturers and academic institutions support regional growth.

Key players in the market

Some of the key players in the Non-Invasive Ultrasound Neuromodulation Systems Market include BrainSonix Corporation, Insightec Ltd., NaviFUS Corporation, Neurosona, Attune Neurosciences, Spire Therapeutics, Brainbox Ltd., Sonic Concepts, Inc., STORZ MEDICAL AG, Soterix Medical, Inc., FUS Instruments Inc., Openwater, KORUST Co., Ltd., Arrayus Technologies Inc., Chongqing Haifu Medical Technology Co., Ltd., Verasonics, Inc., Koninklijke Philips N.V., and Brainlab AG.

Key Developments:

In October 2026, NaviFUS Corporation announced the inauguration of its first focused ultrasound system in Europe at Centre Léon Bérard in France. The installation supports research into blood-brain barrier opening and brain metastases, expanding clinical research infrastructure for focused ultrasound technologies and their potential neurological applications.

In September 2026, Insightec Ltd. announced that its MR-guided focused ultrasound technology had been used to treat 10,000 patients across Europe, the Middle East, and Africa. The milestone reflects growing clinical utilization of focused ultrasound for neurological movement disorders, although the company's established treatment approach involves tissue ablation rather than non-ablative ultrasound neuromodulation.

In January 2026, BrainSonix Corporation highlighted Department of Defense funding awarded to Dr. Martin Monti for research using its low-intensity focused ultrasound pulsation technology in patients with disorders of consciousness following severe brain injury. The project investigates non-invasive modulation of deep brain circuits associated with arousal and conscious awareness.

Product Types Covered:
• Integrated Ultrasound Neuromodulation Systems
• Portable & Wearable Neuromodulation Systems
• Ultrasound Transducers & Accessories
• Neuromodulation Software & Control Platforms
• Services

Ultrasound Technologies Covered:
• Low-Intensity Focused Ultrasound
• Transcranial Pulsed Ultrasound Stimulation
• Phased-Array Focused Ultrasound
• Single-Element Focused Ultrasound
• Transcranial Pulse Stimulation
• Other Ultrasound Technologies

Treatment Approaches Covered:
• Image-Guided Neuromodulation
• Neuronavigation-Guided Neuromodulation
• Open-Loop Neuromodulation
• Closed-Loop Neuromodulation
• Personalized & Adaptive Neuromodulation
• Other Treatment Approaches

Clinical Applications Covered:
• Neurological Disorders
• Psychiatric Disorders
• Chronic Pain Management
• Stroke Rehabilitation
• Disorders of Consciousness
• Neuroscience Research & Brain Mapping
• Other Clinical Applications

End Users Covered:
• Hospitals & Health Systems
• Neurology & Neurosurgery Centers
• Psychiatric & Mental Health Clinics
• Rehabilitation & Pain Management Centers
• Academic Medical Centers & Research Institutions
• Other End Users

Regions Covered:
• North America
o United States
o Canada
o Mexico
• Europe
o United Kingdom
o Germany
o France
o Italy
o Spain
o Netherlands
o Belgium
o Sweden
o Switzerland
o Poland
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Thailand
o Malaysia
o Singapore
o Vietnam
o Rest of Asia Pacific
• South America
o Brazil
o Argentina
o Colombia
o Chile
o Peru
o Rest of South America
• Rest of the World (RoW)
o Middle East
 Saudi Arabia
 United Arab Emirates
 Qatar
 Israel
 Rest of Middle East
o Africa
 South Africa
 Egypt
 Morocco
 Rest of Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances